Solid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease
Correspondence: drserran@ucm.es (D.R.S.); aikaterini.lalatsa@strath.ac.uk (A.L.); Tel.: +44-141-548-2675 (A.L.).
Spremljeno u:
| Glavni autor: | |
|---|---|
| Daljnji autori: | , , , , , |
| Format: | article |
| Jezik: | engleski |
| Izdano: |
2022
|
| Teme: | |
| Online pristup: | https://doi.org/10.3390/pharmaceutics14091822 http://hdl.handle.net/20.500.14066/4744 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
| _version_ | 1870885388501909504 |
|---|---|
| author | Rolón, Miriam Soledad |
| author2 | Hanna, Eustine Vega Gómez, María Celeste Coronel, Cathia Cecilia Dea-Ayuela, María Auxiliadora Serrano, Dolores Remedios Lalatsa, Aikaterini |
| author2_role | author author author author author author |
| author_browse | Coronel, Cathia Cecilia Dea-Ayuela, María Auxiliadora Hanna, Eustine Lalatsa, Aikaterini Rolón, Miriam Soledad Serrano, Dolores Remedios Vega Gómez, María Celeste |
| author_facet | Rolón, Miriam Soledad Hanna, Eustine Vega Gómez, María Celeste Coronel, Cathia Cecilia Dea-Ayuela, María Auxiliadora Serrano, Dolores Remedios Lalatsa, Aikaterini |
| author_role | author |
| bitstream.checksum.fl_str_mv | 8345f2d4d5ef66851702e7d623afd6ba 5b3b3fa3bc64fc8c2ed1023d3a9ebaf0 0175ea4a2d4caec4bbcc37e300941108 858b22fda432bd774e469302988c1974 9317cfc839423f3c7831d80996cdd5cb 50c2624ee8ad90af8c1c54c8db8956a6 c87c7e56a7233e4075a665b03e52ddc2 |
| bitstream.checksumAlgorithm.fl_str_mv | MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
| bitstream.url.fl_str_mv | http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/1/Solid%20nanomedicines%20of%20nifurtimox%20and%20benznidazole%20for%20the%20oral%20treatment%20of%20Chagas%20disease.pdf http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/4/pharmaceutics-1874945-supplementary.pdf http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/2/license_rdf http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/3/license.txt http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/5/Solid%20nanomedicines%20of%20nifurtimox%20and%20benznidazole%20for%20the%20oral%20treatment%20of%20Chagas%20disease.jpg http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/6/Solid%20nanomedicines%20of%20nifurtimox%20and%20benznidazole%20for%20the%20oral%20treatment%20of%20Chagas%20disease.pdf.txt http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/7/pharmaceutics-1874945-supplementary.pdf.txt |
| dc.contributor.other.es.fl_str_mv | Fundación Moisés Bertoni |
| dc.creator.none.fl_str_mv | Rolón, Miriam Soledad Hanna, Eustine Vega Gómez, María Celeste Coronel, Cathia Cecilia Dea-Ayuela, María Auxiliadora Serrano, Dolores Remedios Lalatsa, Aikaterini |
| dc.date.accessioned.none.fl_str_mv | 2026-01-28T20:13:51Z |
| dc.date.available.none.fl_str_mv | 2026-01-28T20:13:51Z |
| dc.date.issued.none.fl_str_mv | 2022-08-29 |
| dc.format.extent.es.fl_str_mv | 25 páginas |
| dc.identifier.citation.en.fl_str_mv | Rolon, M., Hanna, E., Vega, C., Coronel, C., Dea-Ayuela, M. A., Serrano, D. R., & Lalatsa, A. (2022). Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease. Pharmaceutics, 14(9), Artículo 1822. https://doi.org/10.3390/pharmaceutics14091822 |
| dc.identifier.doi.es.fl_str_mv | 10.3390/pharmaceutics14091822 |
| dc.identifier.issn.es.fl_str_mv | 1999-4923 |
| dc.identifier.other.es.fl_str_mv | https://doi.org/10.3390/pharmaceutics14091822 |
| dc.identifier.uri.none.fl_str_mv | http://hdl.handle.net/20.500.14066/4744 |
| dc.language.iso.es.fl_str_mv | eng |
| dc.publisher.es.fl_str_mv | Multidisciplinary Digital Publishing Institute |
| dc.relation.projectCONACYT.es.fl_str_mv | 14-INV-022 |
| dc.rights.*.fl_str_mv | Atribución/Reconocimiento 4.0 Internacional |
| dc.rights.accessRights.es.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.rights.uri.*.fl_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| dc.subject.classification.en.fl_str_mv | 6.16. Manufacture of basic pharmaceutical products and pharmaceutical preparations |
| dc.subject.classification.es.fl_str_mv | 6. Producción y tecnología industrial |
| dc.subject.other.es.fl_str_mv | Benznidazole Chagas disease Nifurtimox Self-nanoemulsifying drug delivery systems (SNEDDS) Silicon dioxide (silica) Solid self-nanoemulsifying drug delivery systems (solid-SNEDDS) Trypanosomiasis |
| dc.title.es.fl_str_mv | Solid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease |
| dc.type.es.fl_str_mv | info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| description | Correspondence: drserran@ucm.es (D.R.S.); aikaterini.lalatsa@strath.ac.uk (A.L.); Tel.: +44-141-548-2675 (A.L.). |
| eu_rights_str_mv | openAccess |
| format | article |
| id | CONACYT_a09c74abf705bf5ba552bed51474a590 |
| identifier_str_mv | Rolon, M., Hanna, E., Vega, C., Coronel, C., Dea-Ayuela, M. A., Serrano, D. R., & Lalatsa, A. (2022). Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease. Pharmaceutics, 14(9), Artículo 1822. https://doi.org/10.3390/pharmaceutics14091822 1999-4923 10.3390/pharmaceutics14091822 |
| language | eng |
| network_acronym_str | CONACYT |
| network_name_str | Repositorio Institucional CONACYT |
| oai_identifier_str | oai:repositorio.conacyt.gov.py:20.500.14066/4744 |
| publishDate | 2022 |
| publishDateSort | 2022 |
| repository.mail.fl_str_mv | repositorio.institucional@conacyt.gov.py |
| repository.name.fl_str_mv | Repositorio Institucional CONACYT |
| repository_id_str | |
| rights_invalid_str_mv | Atribución/Reconocimiento 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ |
| spelling | 1006600b9989b8e-135a-4e53-ab6c-8ea6ac6c767160011456000000-0001-6291-431630860056febdfa-3c70-44ab-81fe-39d6b72b5eac6005ee82ae5-7a4a-4512-8eea-07e811a9c45460016c0875f-dae8-41b6-aecf-e11c995c789b600Fundación Moisés Bertoni2026-01-28T20:13:51Z2026-01-28T20:13:51Z2022-08-29Rolon, M., Hanna, E., Vega, C., Coronel, C., Dea-Ayuela, M. A., Serrano, D. R., & Lalatsa, A. (2022). Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease. Pharmaceutics, 14(9), Artículo 1822. https://doi.org/10.3390/pharmaceutics140918221999-4923https://doi.org/10.3390/pharmaceutics14091822http://hdl.handle.net/20.500.14066/474410.3390/pharmaceutics14091822Correspondence: drserran@ucm.es (D.R.S.); aikaterini.lalatsa@strath.ac.uk (A.L.); Tel.: +44-141-548-2675 (A.L.).This article belongs to the Section Nanomedicine and Nanotechnology.Chagas disease (CD) is a parasitic zoonosis endemic in Central and South America affecting nearly 10 million people, with 100 million people at high risk of contracting the disease. Treatment is only effective when received at the early stages of the disease and it involved two drugs (nifurtimox (NFX) and benznidazole (BNZ)). Both treatments require multiple daily administrations of high doses, suffer from variable efficacy and insufficient efficacy in chronic CD, many side effects, and a very long duration of treatment that results in poor compliance, while combined available therapies that lead to reduced duration of treatment are not available and polypharmacy reduces compliance and increases the cost further. Here we present self-nanoemulsified drug delivery systems (SNEDDS) able to produce easily scalable combined formulations of NFX and BNZ that can allow for tailoring of the dose and can be easily converted to oral solid dosage form by impregnation on mesoporous silica particles. SNEDDS demonstrated an enhanced solubilisation capacity for both drugs as demonstrated by flow-through studies and in vitro lipolysis studies. High loading of SNEDDS to Syloid 244 and 3050 silicas (2:1 w/w) allowed clinically translatable amounts of both NFX and BNZ to be loaded. Tablets prepared from NFX-BNZ combined SNEDDS loaded on Syloid 3050 silicas demonstration near complete dissolution in the flow through cell apparatus compared to NFX and BNZ commercial tablets respectively (Lampit® and Rochagan®). NFX-BNZ-SNEDDS demonstrated nanomolar efficacy in epimastigotes and amastigotes of T. cruzi with acceptable selectivity indexes and demonstrated enhanced survival and reduced parasitaemia in acute murine experimental models of CD. Thus, the results presented here illustrate the ability for an easily scalable and personalised combination oral therapy prepared from GRAS excipients, enabling treatment access worldwide for the treatment of CD.Consejo Nacional de Ciencia y TecnologíaPrograma Paraguayo para el Desarrollo de la Ciencia y Tecnología. Programa Nacional de Incentivo a los InvestigadoresPrograma Paraguayo para el Desarrollo de la Ciencia y Tecnología. Proyectos de investigación y desarrollo25 páginasengMultidisciplinary Digital Publishing InstituteAtribución/Reconocimiento 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccess© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).6. Producción y tecnología industrial6.16. Manufacture of basic pharmaceutical products and pharmaceutical preparationsBenznidazoleChagas diseaseNifurtimoxSelf-nanoemulsifying drug delivery systems (SNEDDS)Silicon dioxide (silica)Solid self-nanoemulsifying drug delivery systems (solid-SNEDDS)TrypanosomiasisSolid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas diseaseinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion9Pharmaceutics14-INV-02214Rolón, Miriam SoledadHanna, EustineVega Gómez, María CelesteCoronel, Cathia CeciliaDea-Ayuela, María AuxiliadoraSerrano, Dolores RemediosLalatsa, AikateriniORIGINALSolid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease.pdfSolid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease.pdfArtículo científicoapplication/pdf4182314http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/1/Solid%20nanomedicines%20of%20nifurtimox%20and%20benznidazole%20for%20the%20oral%20treatment%20of%20Chagas%20disease.pdf8345f2d4d5ef66851702e7d623afd6baMD51pharmaceutics-1874945-supplementary.pdfpharmaceutics-1874945-supplementary.pdfMaterial suplementarioapplication/pdf233734http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/4/pharmaceutics-1874945-supplementary.pdf5b3b3fa3bc64fc8c2ed1023d3a9ebaf0MD54CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/2/license_rdf0175ea4a2d4caec4bbcc37e300941108MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81698http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/3/license.txt858b22fda432bd774e469302988c1974MD53THUMBNAILSolid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease.jpgSolid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease.jpgArtículo científicoimage/jpeg544574http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/5/Solid%20nanomedicines%20of%20nifurtimox%20and%20benznidazole%20for%20the%20oral%20treatment%20of%20Chagas%20disease.jpg9317cfc839423f3c7831d80996cdd5cbMD55TEXTSolid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease.pdf.txtSolid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease.pdf.txtExtracted texttext/plain95232http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/6/Solid%20nanomedicines%20of%20nifurtimox%20and%20benznidazole%20for%20the%20oral%20treatment%20of%20Chagas%20disease.pdf.txt50c2624ee8ad90af8c1c54c8db8956a6MD56pharmaceutics-1874945-supplementary.pdf.txtpharmaceutics-1874945-supplementary.pdf.txtExtracted texttext/plain8279http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4744/7/pharmaceutics-1874945-supplementary.pdf.txtc87c7e56a7233e4075a665b03e52ddc2MD5720.500.14066/4744oai:repositorio.conacyt.gov.py:20.500.14066/47442026-01-29 02:17:22.841Repositorio Institucional CONACYTrepositorio.institucional@conacyt.gov.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 |
| spellingShingle | Solid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease Rolón, Miriam Soledad 6. Producción y tecnología industrial 6.16. Manufacture of basic pharmaceutical products and pharmaceutical preparations Benznidazole Chagas disease Nifurtimox Self-nanoemulsifying drug delivery systems (SNEDDS) Silicon dioxide (silica) Solid self-nanoemulsifying drug delivery systems (solid-SNEDDS) Trypanosomiasis |
| status_str | publishedVersion |
| title | Solid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease |
| title_full | Solid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease |
| title_fullStr | Solid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease |
| title_full_unstemmed | Solid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease |
| title_short | Solid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease |
| title_sort | Solid nanomedicines of nifurtimox and benznidazole for the oral treatment of Chagas disease |
| topic | 6. Producción y tecnología industrial 6.16. Manufacture of basic pharmaceutical products and pharmaceutical preparations Benznidazole Chagas disease Nifurtimox Self-nanoemulsifying drug delivery systems (SNEDDS) Silicon dioxide (silica) Solid self-nanoemulsifying drug delivery systems (solid-SNEDDS) Trypanosomiasis |
| url | https://doi.org/10.3390/pharmaceutics14091822 http://hdl.handle.net/20.500.14066/4744 |